Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Alliance Plan QHP Formulary Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealth Alliance Plan (HAP)Policy N/A

    Qualified Health Plan (QHP) Prescription Drug Formulary Coverage Criteria

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the prescription drugs covered for HAP Qualified Health Plans (ACA-compliant), including formulary tiers, prior authorization, quantity limits, step therapy, specialty pharmacy requirements, and exclusions; affects members and prescribing providers for HAP QHP products.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyQualified Health Plan (QHP) Prescription Drug Formulary Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when a drug is labeled PA; without PA the plan may not cover the drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10/1/2025formulary effective/current snapshot date
    Tier 1-7defined formulary tiers
    30-daytypical max supply for specialty
    PA/QL/SP/STutilization flags present
    QL examplesquantity limit examples

    Coverage criteria and formulary conditions

    General coverage conditions

    Covered when ALL of the following are met:

    Formulary coverage general conditions: Drug appears on the HAP formulary and the member is eligible under the plan.

    Tier placement determines cost sharing (Tier 1–Tier 7).

    Utilization management requirements: All utilization controls shown on the formulary entry for the drug (e.g., PA, QL, ST, SP, TD, HCR) are satisfied prior to coverage.per product as listed

    PA = Prior Authorization; QL = Quantity Limits; ST = Step Therapy; SP = Specialty Pharmacy (Pharmacy Advantage).

    Site-of-care considerations: If the drug is administered in a medical setting (infusion/office/hospital) it may be covered under the medical benefit (Tier 7) rather than the outpatient formulary.
    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyQualified Health Plan (QHP) Prescription Drug Formulary Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization (PA) when a drug is labeled PA; without PA the plan may not cover the drug.
    SourceLink
    On This Page
    Coverage criteria and formulary conditionsFormulary indicators, codes, and supply rulesPrior authorization, step therapy, and documentation requirementsQuantity limits and per-fill supply rulesWhere drugs are covered and specialty sourcingLegend and abbreviationsStep therapy program flags and tablePolicy background and scope

    Medical-administered drugs follow medical benefit rules and may require specialty procurement per formulary notes.

    Exceptions for non-formulary drugs

    Exception requests and handling:

    Non-formulary exception request: If a drug is not on the formulary, the member or provider may request a formulary exception.

    Requests must be submitted to HAP for clinical review; if approved, non-formulary medications process at the highest applicable copayment (highest non-specialty or highest specialty copayment as applicable).

    Supply limits for approved exceptions: Approved non-formulary drugs are limited to a 30‑day supply per fill unless otherwise specified.30-day supply

    Non-formulary specialty drugs when approved may be required to be dispensed by Pharmacy Advantage and limited to 30-day supplies.

    Formulary utilization controls

    Coverage subject to the utilization controls listed on each formulary entry:

    Prior authorization (PA): Drugs annotated 'PA' require prior authorization before the plan will cover them.PA documented

    Examples include fidaxomicin (DIFICID), XENLETA, and XIFAXAN formulations; PA criteria are defined in PA policy documents.

    Quantity limits (QL): Drugs annotated with QL must be dispensed within the specified quantity limits on the formulary entry.per drug QL (e.g., DIFICID 20 tabs/30 days; XENLETA 10 tabs/30 days; XIFAXAN 60 tabs/30 days)

    Requests exceeding QL may be denied or require additional review.

    Specialty sourcing (SP): Drugs marked 'SP' must be obtained through Pharmacy Advantage specialty channel for coverage to apply.SP sourcing via Pharmacy Advantage

    Pharmacy Advantage contact and up to 30‑day supply guidance provided in formulary legend.

    Step therapy (ST) where indicated: When 'ST' is shown the specified step therapy requirements must be met (trial of required agent(s) and documentation of inadequate response or intolerance) before the requested agent will be covered.ST satisfied

    ST is defined in the formulary legend; specific step sequences are applied per product where noted.

    Specialty product coverage with utilization controls

    Specialty injectables and other specialty biologics are covered only when utilization controls and specialty distribution requirements are met:

    Specialty product coverage conditions: Prior Authorization (PA) obtained when required; product obtained via Pharmacy Advantage (SP) when indicated; and dispensed quantities do not exceed product-specific QL limits.varies by product (examples: 1 unit/day; 0.01 unit/day)

    Tier placement determines member cost share; see individual product lines for exact QL, PA, and SP status.

    Formulary controls (PA, QL, SP, ST)

    Apply the NOTES flags on each product line; coverage requires compliance with any of the following as annotated:

    PA and SP controls: Products flagged with PA require prior authorization; products flagged with SP must be obtained through Pharmacy Advantage for coverage.

    Apply PA and SP requirements per product NOTES field (examples: ENTRESTO sprinkle — PA; EVKEEZA — PA and SP; icatibant, VYNDAQEL — PA, SP, QL).

    Quantity limits and TD: Products annotated with QL must be dispensed within the specified limits; TD (transitional) limits for new members apply where noted (one 30‑day fill in first 90 days).per product QL or TD

    Examples: ENTRESTO sprinkle QL 2 tablets/day; VYNDAQEL QL 4 capsules/day; TD applies to some combination products.

    Step therapy and alternatives: If ST or ALT notes appear, the step therapy sequence or required covered alternatives must be followed prior to coverage of the listed product.ST or ALT satisfied

    ALT indicates covered alternatives are listed on the formulary entry and should be considered prior to exception requests.

    Formulary product-level coverage conditions

    Product-level coverage requires ALL applicable product-level conditions be met:

    Product-specific coverage requirements: For the listed product, all of the following apply as shown on the formulary entry: tier assignment (determines cost share), PA if labeled, QL if labeled, SP if labeled, ST if labeled, and TD if labeled for new members.per product as listed in NOTES and QL fields

    Apply these conditions exactly as annotated on the product line; see individual entries for precise QL values, ST/TD rules, and PA documentation requirements.

    The formulary excludes certain categories of products from coverage. Specifically, drug products used for cosmetic purposes, over-the-counter medications (unless specifically listed), experimental drugs or drugs used experimentally, and replacement of lost or stolen medication are not covered under the outpatient formulary as stated in the benefit limitations.

    Drugs designated Non‑Formulary are not on the preferred outpatient formulary and therefore have limited or no preferred coverage; providers or members may request a formulary exception. If an exception is approved by a HAP clinical specialist, the non‑formulary drug may be covered but typically at the higher non‑formulary or specialty cost sharing applicable to that product, and specialty non‑formulary agents when approved are often required to be dispensed via Pharmacy Advantage with standard supply limits (e.g., up to a 30‑day supply).

    Certain antimalarial agents are listed with an indication-specific limitation: these products are Covered for Malaria Treatment, not prophylaxis. Examples in the formulary explicitly state this restriction and include quantity limits tied to the treatment indication rather than prophylactic use.

    Examples of products listed as Non‑Formulary in the outpatient formulary include inhalation/nebulization therapies and other specialized agents such as TOBI PODHALER inhalation capsule (noted Non‑Formulary with QL/SP) and MESNEX oral tablet 400 mg (Non‑Formulary). The listing also contains Non‑Formulary examples among antihistamines and branded allergy products.

    Several branded products are shown as Non‑Formulary or otherwise non‑preferred in the listing; examples include branded oral combo packs and antibiotics such as DIFICID (fidaxomicin) 200 mg entries (Non‑Formulary notation appears in nearby lines) and other branded oncology/topical agents identified as non‑formulary in the document.

    The formulary identifies multiple agents assigned to higher tiers or explicitly Non‑Formulary / Tier 7 (Medical Coinsurance) status. Examples called out in the listing include agents such as NEXAVAR and other brand oncology products flagged Non‑Formulary or Tier 7, which indicates higher member cost‑sharing or medical‑benefit handling.

    Several specialty agents are listed as Non‑Formulary while also carrying specialty sourcing and utilization controls. Illustrative specialty examples in the immunoglobulin and biologics section include ASCENIV 10%, GAMMAGARD products, and GAMUNEX‑C, many of which are annotated with SP (specialty distribution), PA, and QL requirements.

    The formulary lists multiple immunoglobulin and vaccine products among Non‑Formulary or specialty entries. Examples include PRIVIGEN, XEMBIFY, and vaccine entries such as TYPHIM VI and VIVOTIF, which are shown as Non‑Formulary or annotated with program notes (HCR, SP) where applicable.

    Additional Non‑Formulary examples across the listing include products such as TYPHIM VI intramuscular solution, VIVOTIF oral capsule, and epinephrine auto‑injector brands (EPIPEN entries are noted as Non‑Formulary while auto‑injector QL limits are listed), demonstrating the variety of non‑preferred items captured in the formulary.

    The document also lists assorted Non‑Formulary products across therapeutic classes (for example, certain cognitive disorder combinations and cardiovascular agents). These entries (e.g., memantine‑donepezil formulations; TOPROL XL) are marked Non‑Formulary or show ALT/QL notes indicating restricted or alternative coverage approaches.

    Further Non‑Formulary examples include multiple high‑cost specialty clotting factor and hemostasis products; the listing shows items such as HYMPAVZI PEN, IDELVION, and REBINYN assigned Non‑Formulary status or Non‑Formulary tiering while also carrying SP, PA, and QL annotations.

    Summarizing branded Non‑Formulary examples, the formulary contains many specialty and branded agents (including clotting factors, biologics, and selected cardiovascular or oncology drugs) that are flagged Non‑Formulary and subject to specialty procurement, prior authorization, or quantity limits as annotated per product.

    Non‑Formulary coverage may be conditional where a covered alternative (ALT) or a prior authorization is available. The listing shows multiple Non‑Formulary entries with an ALT noted (covered alternatives) or with PA requirements; when an approved ALT or PA exists, the plan may permit coverage under the formulary exception process.

    The formulary explicitly states that experimental drugs and drugs used experimentally are not covered. This general exclusion is separate from Non‑Formulary handling and applies across the outpatient formulary.

    Within the extracted segment there is no discrete block that uses the phrase 'not medically necessary' to define coverage denial; the document primarily relies on formulary tiering, utilization controls, and explicit exclusion language to indicate coverage limits.

    The extract does not include a comprehensive, stand‑alone Not Medically Necessary (NMN) policy statement for specific services or drugs; instead, non‑formulary designation and program flags imply limited coverage or alternative handling where NMN determinations would otherwise apply.

    The formulary contains indication‑specific limitations for certain products. For example, the quinidine and several antimalarial entries are annotated as Covered for Malaria Treatment; not prophylaxis. Other entries show similar indication‑level constraints reflected in the NOTES field and in associated quantity limits.

    Formulary indicators, codes, and supply rules

    Formulary indicators and abbreviationsmixed
    PAPrior Authorization
    QLQuantity Limits
    STStep Therapy
    SPSpecialty Pharmacy (Pharmacy Advantage)
    HCRHealth Care Reform (preventive zero cost share rules)
    TDTransition Drug: one 30-day fill in first 90 days for new members
    PFPartial Fill Program
    AGAge Restriction
    Sample drug entries and annotations (examples)mixed
    examplesFormulary drug entries (e.g., acetylcysteine solution, BAQSIMI nasal spray, GVOKE auto-injectors, penicillamine, ELMIRON) with tier and notes (PA, QL, SP, ALT).
    Formulary drug entries (partial)mixed
    DIFICID 200 mgfidaxomicin oral tablet 200 mg (PA; QL 20 tablets per 30 days)
    linezolid 600 mglinezolid oral tablet 600 mg (Tier 2; QL 2 tablets per day)
    XENLETA 600 mgXENLETA oral tablet 600 mg (PA; QL 10 tablets per 30 days)
    XIFAXAN 200 mgXIFAXAN oral tablet 200 mg (PA; SP; QL per 30 days)
    XIFAXAN 550 mgXIFAXAN oral tablet 550 mg (PA; SP; QL 60 tablets per 30 days)
    BAXDELA 450 mgBAXDELA oral tablet 450 mg (Non-Formulary; QL applies)
    colistin injection 150 mgcolistin (colistimethate na) injection recon soln 150 mg (Tier 6; QL 2 mL per 28 days of treatment in 180 days; SP)
    fosfomycin 3 gramfosfomycin tromethamine oral packet 3 gram (Tier 2; QL 1 packet per 30 days)
    nitrofurantoin 100 mgnitrofurantoin macrocrystal 100 mg (Tier 2; QL 4 capsules per day)
    Drug listing (no procedure/diagnosis codes present)mixed
    No codes listed
    Formulary tier labels and legend (no billing codes)mixed
    No codes listed
    Drug listings (no billing codes provided in this part)mixed
    No codes listed
    Formulary drug entries with special controlsmixed
    ENTRESTO SPRINKLE ORAL PELLET 15-16 MG, 6-6 MGListed with NOTES = PA; QL (2 tablets per 1 day)
    sacubitril-valsartan oral tablet 24-26 mg, 49-51 mg, 97-103 mgDRUG TIER = 2; NOTES = TD; QL (2 Tablet per 1 day)
    EVKEEZA INTRA VENOUS SOLUTION 150 MGMMLDRUG TIER = Non-Formulary; NOTES = PA; SP
    icatibant subcutaneous syringe 30 ml mg/3DRUG TIER = 5; NOTES = PA; SP; QL (0.01 ML per 1 day)
    VYNDAQEL ORAL CAPSULE 20 MGNOTES = PA; SP; QL (4 capsules per 1 day)
    Formulary drug entries (selected examples from chunk)mixed
    acetazolamide 500 mg ER capsuleacetazolamide oral capsule, extended release 500 mg (Tier 2)
    acetazolamide 125/250 mg tabletacetazolamide oral tablet 125 mg, 250 mg (Tier 2)
    ASPRUZYO 500/1000 mgASPRUZYO SPRINKLE ORAL EXTEND RELEASE GRANULES, PACKET 500 mg, 1000 mg (Non-Formulary; ALT: Ranolazine ER)
    CAMZYOS 2.5/5/10/15 mgCAMZYOS ORAL CAPSULE (PA; SP; QL 1 capsule per day)
    ranolazine ER 500/1000 mgranolazine oral tablet extended release 12 hr 500 mg, 1000 mg (Tier 2; QL 2 tablets per day)
    VYNDAQEL 20 mgVYNDAQEL ORAL CAPSULE 20 mg (PA; SP; QL 4 capsules per day)
    CORLANOR 5 mg/5 mlCORLANOR ORAL SOLUTION 5 mg/5 mL (Non-Formulary; QL applies)
    ivabradine 5/7.5 mgivabradine oral tablet 5 mg, 7.5 mg (Tier 4; QL 2 tablets per day)
    colchicine 0.6 mgcolchicine oral capsule/tablet 0.6 mg (capsule Non-Formulary with ALT; tablet Tier 2; QL 4 per day)
    COLCRYS 0.6 mgCOLCRYS ORAL TABLET 0.6 mg (Non-Formulary; ALT listed; QL 4 per day)
    1–10 of 14
    1/2
    Specialty/injectable supply limits (typical)
    Specialty/injectable supply limitTypically limited to a 30-day supply per fill; some specialty drugs require a 15-day first fill.
    ELMIRON 100 mgPA required; QL = 3 capsules per day.
    Penicillamine 250 mgTier 2; PA and SP noted; QL = 4 tablets per day.
    Quantity limits examples (capsules/ampules/mL)
    Tobramycin inhalation/nebulization productsQL = 280 ampules per 30 days for inhalation presentations; PA and SP may apply.
    Bethkis inhalation solutionNotes = QL (Quantity Limits Apply); QL (280 ampules per 30 days).
    Gentamicin topical/ophthalmic examplesQL examples include 30 g per 30 days for topical cream; 5 mL per fill for ophthalmic suspension.
    Example quantity limits (selected products)
    AlbendazoleQL = 120 tablets per 28 days of treatment per 180 days.
    SIRTURO (bedaquiline) 100 mgQL = 4 tablets per 180 days of treatment in 365 days.
    CRESEMBA oral capsule 186 mgPA noted; QL = 70 capsules per 30 days (70 capsules per 1 fill).
    Quantity limits examples (varied products)
    EMTRIVA oral solutionQL = 680 mL per 23 days.
    NOXAFIL oral suspension 200 mg/5 mLQL = 105 mL per 1 fill.
    Fosfomycin tromethamine 3 g packetQL = 1 packet per 30 days.
    Example quantity limits and special-control products
    ENTRESTO SPRINKLE ORAL PELLET (15-16 mg, 6-6 mg)NOTES = PA; QL = 2 tablets per day.
    EVKEEZA INTRAVENOUS SOLUTION 150 mg/mLDRUG TIER = Non-Formulary; NOTES = PA; SP.
    Icatibant subcutaneous syringe 30 mL mg/3NOTES = PA; SP; QL examples shown as small mL per day (e.g., 0.01 mL per day in similar entries).
    VYNDAQEL ORAL CAPSULE 20 mgNOTES = PA; SP; QL = 4 capsules per day.
    Acetazolamide formulationsacetazolamide 500 mg ER capsule and acetazolamide 125/250 mg tablets listed (Tier 2) with QL as noted per product.

    Prior authorization, step therapy, and documentation requirements

    Prior Authorization

    Prior Authorization (PA) overview

    Certain drugs listed on the formulary are designated "PA" and require prior authorization before coverage; without prior approval the plan may not cover the drug. PA indicators appear in the NOTES field for each product and must be satisfied prior to dispensing.

    • PA = Prior Authorization per formulary legend; see NOTES on product lines for PA flags.
    Prior Authorization

    Prior authorization required for selected products (examples)

    Providers must obtain prior authorization for multiple specific products noted with PA in the NOTES (examples shown include ELMIRON capsules and tobramycin inhalation products).

    • ELMIRON oral capsule 100 mg — NOTES = PA; QL (3 capsules per 1 day).
    • Tobramycin inhalation/nebulization products — NOTES include PA; SP; QL (280 ampules per 30 days).
    Prior Authorization

    Prior authorization requirement (topical/systemic and specialty antifungals)

    Topical, systemic and specialty antifungals and similar agents marked 'PA' in their NOTES require prior authorization before coverage and dispensing.

    • CRESEMBA oral capsule 186 mg — NOTES = PA; QL (70 capsules per 1 fill).
    • NOXAFIL oral suspension — NOTES = PA; QL (105 mL per 1 fill).
    Prior Authorization

    Prior authorization required for listed products (CRESEMBA, NOXAFIL, etc.)

    Several specific products are listed with PA in the NOTES (examples include CRESEMBA, NOXAFIL, LIVTENCITY and other agents); prescribers must secure PA when those NOTES indicate it.

    • CRESEMBA ORAL CAPSULE 186 MG — NOTES = PA; QL 70 capsules per 1 fill.
    • NOXAFIL ORAL SUSPENSION 200 MG/5 ML — NOTES = PA; QL 105 mL per 1 fill.
    • LIVTENCITY ORAL TABLET 200 MG — NOTES = PA; QL (4 tablets per day).
    Prior Authorization

    Prior Authorization required for select agents (DESCOVY, PEGASYS, examples)

    Select agents in the antiviral/antiretroviral and other classes are annotated with PA; providers must obtain authorization for those agents prior to dispensing.

    • DESCOVY ORAL TABLET 200-25 MG — NOTES = PA; QL (1 tablet per 1 day).
    • PEGASYS SUBCUTANEOUS SYRINGE — NOTES = PA; SP; QL (2 mL per 30 days).
    Prior Authorization

    PA required for PA-designated drugs (fidaxomicin, XIFAXAN examples)

    Drugs designated with PA in the formulary (examples shown include fidaxomicin and XIFAXAN formulations) must have prior authorization obtained before coverage is provided.

    • DIFICID (fidaxomicin) ORAL TABLET 200 MG — NOTES = PA; QL (20 tablets per 30 days).
    • XIFAXAN ORAL TABLET 550 MG — NOTES = PA; SP; QL (60 tablets per 30 days).
    Prior Authorization

    Prior authorization and specialty routing required for many oncology agents

    Many specialty oncology agents require prior authorization and, where flagged SP, must be obtained through the Pharmacy Advantage specialty channel; providers must coordinate PA and specialty routing.

    • CABOMETYX ORAL TABLET 20 MG — NOTES = PA; SP; QL (30 tablets per 30 days).
    • ERIVEDGE ORAL CAPSULE 150 MG — NOTES = PA; SP; QL (30 capsules per 30 days).
    Prior Authorization

    Prior authorization required for listed drugs (specialty/oncology)

    Numerous specialty and oncology products are annotated with PA in the NOTES; prescribers must obtain prior authorization per the product-level note before dispensing.

    • PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML — NOTES = PA; SP; QL (2 mL per 30 days).
    • PEMAZYRE ORAL TABLET — NOTES = PA; SP; QL (14 tablets per 21 days).
    Prior Authorization

    Prior Authorization required for multiple specialty products (immunoglobulins, vaccines)

    Many immunoglobulin products and vaccines in the formulary are flagged PA and/or SP; providers must obtain prior authorization and arrange specialty procurement where NOTES indicate SP.

    • GAMMAGARD LIQUID INJECTION SOLUTION 10% — NOTES = PA; SP; QL (1 mL per 28 days).
    • CUVITRU SUBCUTANEOUS SOLUTION — NOTES = PA; QL (0.01 mL per 1 day); SP.
    Prior Authorization

    Prior authorization required (example: TRELEGY ELLIPTA)

    Products marked 'PA' in the NOTES (for example TRELEGY ELLIPTA) require prior authorization before coverage; prescribers must secure PA as indicated.

    • TRELEGY ELLIPTA — NOTES = PA; TD; QL (1 device per 30 days).
    Prior Authorization

    Prior authorization required (prescriber action reminder)

    Prescribers must obtain prior authorization for products annotated with 'PA' in the NOTES prior to dispensing; PA is a required administrative step per formulary legend.

    • Prescribers must secure PA for drugs annotated PA in NOTES before dispensing to avoid non-coverage.
    Prior Authorization

    PA required for many specialty hematologic agents

    Many specialty hematologic agents are noted with PA and often SP; prior authorization must be obtained and specialty channel arranged where indicated.

    • NEUPOGEN injection syringes — NOTES = PA; SP; QL (4 syringes per 1 fill).
    • Eltrombopag products — NOTES = PA; SP; QL as shown per presentation.
    Prior Authorization

    Prior Authorization required for many specialty products

    Many listed injectable and specialty products require prior authorization before coverage; check product-specific NOTES for PA requirements and applicable quantity limits.

    • Hemofil M, Jivi, Novoseven RT and similar products — NOTES = PA; SP; QL (commonly 1 unit per day or product-specific unit rules).
    Prior Authorization

    Prior authorization required for selected specialty drugs

    Certain specialty drugs (e.g., ENTRESTO sprinkle pellet, EVKEEZA IV, icatibant) are flagged PA in NOTES and require prior authorization; specialty channel enrollment is required when SP is noted.

    • ENTRESTO SPRINKLE ORAL PELLET — NOTES = PA.
    • EVKEEZA INTRAVENOUS SOLUTION — NOTES = PA; SP.
    Prior Authorization

    Prior authorization, QL, and ST requirements summarized

    Some products listed with NOTES include PA plus QL and/or ST; providers must obtain prior authorization and ensure quantity limits and step therapy requirements (where annotated ST) are met for coverage.

    • ATTRUBY, CAMZYOS, VYNDAQEL — NOTES indicate PA; QL; SP where applicable and ST when shown in legend.
    Step Therapy

    Step Therapy (ST) overview

    Step therapy (ST) is indicated in the formulary legend and may require trial of specified drugs before coverage of alternative agents; providers must follow ST edits where an individual product is annotated with ST.

    • ST = Step Therapy Required per formulary legend; specific step sequences are noted on product entries where applicable.
    Step Therapy

    Step therapy - legend present

    The formulary legend defines ST (Step Therapy Required); providers should check product-specific NOTES for ST flags and follow required step edits before requesting coverage for later-line drugs.

    • ST flag appears in legend; check individual product NOTES for ST designation.
    Step Therapy

    Step therapy program flag (provider must follow step edits)

    The formulary uses an ST program flag for some drugs; when a product is annotated with ST the prescriber must demonstrate trials of required first-line agents per the step edit before the alternative will be covered.

    • Example: certain amlodipine-atorvastatin combinations include ST in NOTES and require satisfying step therapy edits.
    Step Therapy

    Step therapy present (provider obligation)

    Step therapy controls apply to some formulary drugs; providers must document prior trials and failures of required agents when submitting coverage requests for ST-designated products.

    • ST indicated in legend — documentation of prior step drug trial is required for coverage of ST-marked products.
    Step Therapy

    Step therapy referenced in legend

    The formulary legend references Step Therapy (ST); where an entry is annotated ST providers must follow the step edit sequence specified in the full formulary to obtain coverage.

    • ST is defined in the legend; verify product NOTES for ST designation and required prior agents.
    Step Therapy

    Step therapy program note (follow step edits)

    Items annotated 'ST' require completion of specified prior steps before coverage; providers must follow those step therapy requirements and include documentation of prior therapy when requesting coverage.

    • WELCHOL packet (example) — NOTES = ST; QL (7 tablets per 1 day).
    Step Therapy

    Step therapy present (examples: combination products)

    Some products are marked ST in product entries (for example certain combination antihypertensive products); providers must satisfy step therapy edits before alternatives will be covered.

    • Amlodipine-atorvastatin entries — NOTES = TD; ST; QL (1 tablet per day) for some strengths.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    How to request prior authorization or exception

    Submit prior authorization or formulary exception requests using the forms available at hap.org/providers; the request must include clinical justification and supporting documentation.

    • Use HAP provider forms at hap.org/providers to request PA or exception and include clinical rationale.
    Documentation Required

    Required documentation and administrative contact

    When submitting PA or dispensing claims, providers and pharmacies must follow the formulary legend: PA = Prior Authorization; QL = Quantity Limits; SP = obtain via Pharmacy Advantage (contact provided).

    • Pharmacy Advantage specialty contact: (800) 456-2112 for SP items.
    Documentation Required

    Prior authorization required for some drugs (documented)

    Products flagged 'PA' require prior authorization documentation before coverage; include clinical support and reference the product NOTES when submitting requests.

    • PA flag on product NOTE indicates authorization is required prior to coverage.
    Documentation Required

    EUA exception for Paxlovid

    The EUA-approved PAXLOVID product is noted as not requiring an authorization days prior; providers should note this exception when ordering PAXLOVID under EUA.

    • PAXLOVID DOSE PACK — NOTES = PA; QL (5 courses per 180 days); EUA-approved product does not require an authorization days prior.
    Documentation Required

    Specialty pharmacy sourcing documentation

    Drugs marked SP must be obtained through Pharmacy Advantage; providers must arrange specialty pharmacy sourcing and may need to document the dispensing source with PA submissions.

    • SP = This drug can only be obtained at Pharmacy Advantage: (800) 456-2112; up to 30-day supply per fill.
    • Examples: EVKEEZA, many IVIGs and clotting factors are SP and require Pharmacy Advantage procurement.
    Documentation Required

    PA and QL documentation (provider/pharmacy responsibilities)

    When requesting PA or submitting claims for PA/QL items, prescribers and pharmacies must provide documentation supporting the PA and ensure quantities do not exceed the QL specified for the product.

    • Examples: CRESEMBA QL = 70 capsules per 1 fill; DIFICID QL = 20 tablets per 30 days — claims exceeding these limits may be denied without supporting documentation.
    Documentation Required

    Required routing and documentation for SP items

    Prescribers and pharmacies must route SP-designated prescriptions through Pharmacy Advantage and comply with product-specific PA and QL notes; contact Pharmacy Advantage for specialty ordering.

    • Pharmacy Advantage phone: (800) 456-2112; SP items limited to up to 30-day supply per fill.
    Documentation Required

    Legend and program flags (use on submissions)

    Refer to the formulary legend when submitting PA or claims: PA = Prior Authorization; QL = Quantity Limits; SP = Pharmacy Advantage specialty distribution; ST = Step Therapy Required; TD = limited initial 30-day fill for new members.

    • Providers must reference these legend flags on PA submissions and claims.
    Billing Rule

    Claims documentation must follow Notes flags

    Pharmacy claims must reflect applicable NOTES flags (PA, SP, QL) and adhere to the product-specific quantity limits; noncompliance may result in claim denial or rejection.

    • Examples of QL formats: '1 ML per 28 days', '1 vial per 30 days', '0.01 ML per 1 day'.
    Note
    Note
    Note
    Note
    Documentation Required

    Prior authorization and specialty pharmacy procurement

    When NOTES include PA or SP, the provider must obtain prior authorization and/or arrange specialty pharmacy supply through Pharmacy Advantage as specified for the product.

    • ENTRESTO SPRINKLE — NOTES = PA; EVKEEZA IV — NOTES = PA; SP; VYNDAQEL — NOTES = PA; SP; QL (4 capsules per day).
    Documentation Required

    PA and SP documentation (provider responsibilities)

    Prescribers must supply clinical documentation to support PA requests where PA is indicated; for SP items verify member status (TD) and supply limits as needed for initial fills.

    • TD = For new to HAP members only: one 30-day fill in the first 90 days of enrollment — verify member status when applicable.
    Denial Risk

    Prior Authorization requirement — failure to obtain may result in non-coverage

    Failure to obtain prior authorization when required may result in the drug not being covered; providers must secure PA for PA-flagged products to avoid non-coverage.

    • PA required per formulary legend; absence of PA can lead to non-coverage.
    Denial Risk

    Denial triggers from formulary status and flags

    Drugs marked Non-Formulary or annotated with PA or SP flags may trigger denial or require special procurement; providers should request exceptions or PA where appropriate to avoid denial.

    • Examples: MESNEX 400 mg — Non-Formulary; VISTOGARD oral granules — Non-Formulary with SP.
    Denial Risk

    Quantity limits and special sourcing may trigger denial

    Requests exceeding stated quantity limits (QL) or not obtained via the designated specialty channel (SP) may be denied; verify QL and sourcing before submission.

    • Example: CRESEMBA QL = 70 capsules per 1 fill; SIRTURO QL rules shown per treatment course.
    Denial Risk

    Requests for drugs listed with 'Non-Formulary' — denial risk

    Requests for drugs listed as Non-Formulary or lacking required PA may be denied or processed under non-formulary rules; obtain PA or request an exception where clinically justified.

    • Non-Formulary status often requires an exception or will be subject to non-formulary handling.
    Denial Risk

    Prior authorization, quantity limits, and specialty distribution can trigger denial

    Coverage for products labeled PA can be restricted unless prior authorization is obtained; QL or SP flags can also cause denials if limits or specialty sourcing requirements are not met.

    • DESCOVY ORAL TABLET 200-25 MG — NOTES = PA; QL (1 tablet per day) — absence of PA or QL noncompliance could limit coverage.
    Denial Risk

    Prior authorization required for PA-designated drugs (denial risk)

    PA-designated drugs may be denied if prior authorization is not obtained; ensure PA is in place for PA-flagged products to prevent claim denials.

    • DIFICID (fidaxomicin) — NOTES = PA; QL (20 tablets per 30 days) — secure PA to prevent denial.
    Denial Risk

    Specialty sourcing requirement (claims may be denied if off-channel)

    Specialty-only drugs (SP) must be obtained through Pharmacy Advantage; claims may be denied or redirected if dispensed outside the designated specialty channel.

    • SP = This drug can only be obtained at Pharmacy Advantage (800-456-2112); examples include many IVIG and clotting-factor products.
    Denial Risk

    Triggers for denial (PA, QL, SP noncompliance)

    Requests involving products marked PA, exceeding QL, or obtained outside Pharmacy Advantage (SP) are among common triggers for denial; providers should verify all notes before prescribing.

    • Examples: oncology agents with PA/SP/QL flags — absence of PA or SP routing or QL overage can cause denial.
    Denial Risk

    Prior authorization triggers (examples)

    Claims may be denied or require prior authorization when product NOTES list PA (examples include PEGASYS, PIQRAY, POMALYST); obtain PA to avoid claim delays or denials.

    • PEGASYS — NOTES = PA; SP; QL (2 mL per 30 days).
    Billing Rule

    Specialty pharmacy requirement (use Pharmacy Advantage)

    Drugs marked 'SP' must be obtained from Pharmacy Advantage; failure to use the designated specialty pharmacy may lead to coverage or dispensing issues.

    • IVIG products and many biologics show NOTES = SP; obtain via Pharmacy Advantage to ensure coverage.
    Denial Risk

    Prior Authorization and Specialty Distribution required for many products

    Coverage or dispensing may be denied or restricted if PA is not obtained for products marked 'PA' or if specialty distribution (SP) requirements are not followed; providers must comply with both PA and SP notes.

    • Examples include many IVIG and specialty biologics — NOTES include PA and SP; both must be satisfied.
    Denial Risk

    Quantity limits (exceedance triggers potential denial)

    Quantity limit exceedance may trigger denials; providers must ensure dispensed quantities do not exceed QL (examples: epinephrine autoinjectors QL = 4 pens per 30 days).

    • EPIPEN 2-PAK — NOTES = QL (4 units per fill).
    • Epinephrine auto-injector entries — QL (4 pens per 30 days).
    Denial Risk

    PA and SP requirements (denial risk)

    Drugs marked PA and those with SP (Pharmacy Advantage specialty distribution) may trigger denial if authorization or specialty sourcing requirements are not met; obtain both PA and SP routing where indicated.

    • Products with combined PA and SP flags require both prior authorization and specialty procurement to avoid denial.
    Denial Risk

    Quantity limit denials (examples)

    Products with QL may be denied if requests exceed specified limits (for example ADVAIR DISKUS QL = 60 units per 30 days; PROAIR RESPICLICK QL = 2 inhalers per 30 days).

    • ADVAIR DISKUS — NOTES = QL (60 units per 30 days).
    • PROAIR RESPICLICK — NOTES = QL (2 inhalers per 30 days).
    Denial Risk

    Formulary restriction risk (Non-Formulary / PA / QL / SP)

    Requests for Non-Formulary products or products with PA/QL/SP/ALT notes may be denied or require authorization; providers should pursue exceptions or alternatives when appropriate.

    • Non-Formulary items may require exception requests; ALT indicates covered alternatives to consider.
    Denial Risk

    Potential denial triggers for specialty injectables

    Specialty injectable clotting-factor products and similar biologics list PA, SP and QL in NOTES; providers must obtain PA and use Pharmacy Advantage as required to avoid denial for these specialty injectables.

    • NOVOSEVEN RT, JIVI, KOGENATE, etc. — NOTES = PA; SP; QL (commonly 1 unit per 1 day).
    Denial Risk

    PA / SP may trigger denial (provider reminder)

    Drugs noted with PA or SP may trigger denial if authorization or specialty procurement requirements are not met; ensure PA is obtained and SP items are sourced via Pharmacy Advantage.

    • ENTRESTO SPRINKLE — NOTES = PA; EVKEEZA IV — NOTES = PA; SP.
    Denial Risk

    Non-Formulary / PA risk (coverage denial possible)

    Non-Formulary tier assignments and missing required prior authorization or unmet step therapy flags may trigger coverage denials if no PA/exception is obtained.

    • Non-Formulary items require exception or will be processed under non-formulary rules — absence of PA or unmet ST can cause denial.

    Quantity limits and per-fill supply rules

    Examples across formulary (Baqsimi, naloxone, glucagon kits, Elmiron, penicillamine)
    BaqsimiQL: 1 kit per fill
    Naloxone (nasal/injectable)QL examples: naloxone nasal spray QL 2 doses per 90 days; alternative formulations flagged ALT/QL
    Elmiron (ELMIRON) 100 mgNotes: PA; QL (3 capsules per 1 day)
    Specialty/injectable drugs supply limits (30-day typical; some 15-day first fill)
    Standard limitSpecialty/injectable drugs (except insulin) and select oral drugs limited to maximum 30-day supply per fill
    First-fill policySome specialty drugs require a 15-day supply for the first fill
    Specialty procurementSP-designated items must be obtained through Pharmacy Advantage (phone provided)
    ELMIRON oral capsule 100 mg QL
    ELMIRON 100 mgNotes: PA; QL (3 capsules per 1 day)
    Tier placementELMIRON listed with Tier = 4 on formulary extract
    Provider actionPA required as noted on product line
    penicillamine oral tablet 250 mg QL
    Penicillamine 250 mgNotes: PA; SP; QL (4 tablets per 1 day)
    Tier placementPenicillamine listed as Tier = 2 (per extract) and flagged Non-Formulary in some entries
    Covered alternativesALT fields reference covered alternatives where applicable
    tobramycin inhalation/nebulization products QL
    Tobramycin inhalation (various)QL: 280 ampules per 30 days for inhalation/nebulization products (PA and SP noted on specific formulations)
    Tobramycin PODHALERNotes indicate SP and QL apply; some PODHALER forms are Non-Formulary
    Nebulization solutionSome inhalation solutions flagged PA; QL varies by product and formulation
    RYALTRIS nasal spray QL
    RYALTRIS nasal sprayNotes: ALT (covered alternatives listed); QL (1 gram per 1 day)
    Tier designationRYALTRIS listed as Non-Formulary in extract
    AlternativesCovered alternatives: various intranasal corticosteroids listed in NOTES
    albendazole QL example
    AlbendazoleQL: 120 tablets per 28 days of treatment per 180 days
    Therapy course limitLimit expressed per treatment course (28 days within 180 days) as noted
    Tier placementAlbendazole listed as Tier = 2 in extract
    SIRTURO (bedaquiline) QL examples
    SIRTURO 100 mgQL: 4 tablets per 180 days of treatment in 365 days (100 mg strength)
    SIRTURO 20 mgQL: 10 tablets per 180 days of treatment in 365 days (20 mg strength)
    Specialty sourcingSP noted for SIRTURO formulations
    CRESEMBA (oral) QL examples
    CRESEMBA oral capsule 186 mgQL: 70 capsules per 30 days; QL (70 capsules per 1 fill); PA noted
    IV formulationCRESEMBA IV recon soln noted with QL per vial across treatment days
    Fill frequencyCRESEMBA oral entry includes 3 fills per 365 days in listing
    SIRTURO 100 mg QL detail
    SIRTURO 100 mg detailQL: 4 tablets per 180 days of treatment in 365 days
    PA/SP flagsProduct entry shows SP and QL; prior authorization may apply per NOTES
    TierListed as Tier = 5 (Preferred Specialty)
    SIRTURO 20 mg QL detail
    SIRTURO 20 mg detailQL: 10 tablets per 180 days of treatment in 365 days
    SP flagSP indicated for specialty sourcing on product line
    Provider noteQuantity expressed per treatment course as shown in NOTES
    CRESEMBA oral capsule 186 mg QL
    CRESEMBA 186 mg capsuleQL: 70 capsules per 30 days; QL (70 capsules per 1 fill); PA indicated
    Multiple formulationsCRESEMBA also listed as IV recon soln with vial-based QL
    Supply frequencyListing indicates up to 3 fills per 365 days for oral capsule in extract
    NOXAFIL oral suspension QL
    NOXAFIL oral suspension 200 mg/5 mLQL: 105 mL per 1 fill; PA and ALT noted
    Oral tablet DRPosaconazole DR tablets listed with QL (2 tablets per 1 day) and ALT
    Formulary statusSome posaconazole formulations listed Non-Formulary with QL
    LIVTENCITY QL (4 tablets per day)
    LIVTENCITY 200 mgQL: 4 tablets per day (PA noted)
    Indication noteListed in CMV antiviral section with PA and QL
    TierListed as Tier = 5 (Preferred Specialty)
    PAXLOVID QL courses per 180 days
    PAXLOVIDQL: 5 courses of treatment per 180 days; EUA-approved product exception does not require authorization days prior
    Dose packPAXLOVID oral tablets supplied as dose pack per product listing
    Provider actionPA noted for product generally though EUA exception applies
    FIRVANQ oral recon soln QL
    FIRVANQ oral recon solnQL: 450 mL per fill; 3 fills per year
    TierFIRVANQ listed as Tier = 3 in extract
    Use limitationQuantity limits specified per fill and annual fill frequency
    VIBATIV IV recon soln QL
    VIBATIV IV recon soln 750 mgQL: 1 vial per 1 day
    TierVIBATIV listed as Tier = 7 (Medical Drugs) in the extract
    Provider actionQuantity limit applies per day as noted in product line
    EMTRIVA oral solution QL
    EMTRIVA oral solution 10 mg/mLQL: 680 mL per 23 days
    DESCOVY 200-25 mgQL: 1 tablet per day; PA noted for some strengths
    GENVOYA/other ARVsMany antiretroviral products listed with QL of 1 tablet per day
    DESCOVY QL example
    DESCOVY 200-25 mgNotes: PA; ALT (alternative emtricitabine-tenofovir formulations); QL (1 tablet per 1 day)
    DESCOVY 120-15 mgAlternate strength listed (notes vary by strength)
    Provider actionPA applies where noted on product line
    EMTRIVA oral solution (value repeated)
    EMTRIVA oral solution (repeat)QL: 680 mL per 23 days (entry repeated in formulary extract)
    TierEMTRIVA listed as Tier = 5 in extract
    DocumentationClaims must reflect QL limits when submitting for coverage
    CAYSTON inhalation solution QL
    CAYSTON inhalation solutionQL: 2 boxes per month
    PA flagSome inhalation products carry PA and ALT notes in formulary
    SP requirementCertain formulations require specialty sourcing (SP)
    oseltamivir oral capsules QL
    Oseltamivir capsulesQL: 10 capsules per fill (some strengths 2 fills per 365 days)
    Oseltamivir suspensionQL: 120 mL per fill (2 fills per 365 days)
    Formulary statusSome Tamiflu strengths listed Non-Formulary with QL limits
    BARACLUDE oral solution QL
    BARACLUDE oral solutionQL: 700 mL per fill; SP noted for some formulations
    Tablet formBaraclude tablets listed Non-Formulary with QL 1 tablet per day in some entries
    Provider actionSP and QL flags indicate specialty sourcing and quantity limits apply
    fidaxomicin (DIFICID) QL
    DIFICID (fidaxomicin) 200 mgQL: 20 tablets per 30 days (PA noted)
    Fidaxomicin PAPA applied to fidaxomicin per product line
    Related alternativesALT options listed include metronidazole and FIRVANQ
    linezolid oral suspension QL
    Linezolid oral suspension 100 mg/5 mLQL: 1800 mL per 30 days
    Linezolid tablet 600 mgQL: 2 tablets per day
    Formulary tierLinezolid listed as Tier = 2 in extract
    linezolid tablet 600 mg QL
    Linezolid 600 mg tabletQL: 2 tablets per day
    PA/QL notesSome oxazolidinone entries include PA and QL flags
    Supply intentQuantity limits apply per day as listed for safety and utilization management
    XENLETA QL
    XENLETA 600 mgQL: 10 tablets per 30 days
    PA flagPA may apply as indicated in NOTES for pleuromutilin class
    Formulary noteQuantity limits referenced in product line for safety monitoring
    XIFAXAN 550 mg QL
    XIFAXAN 550 mgQL: 60 tablets per 30 days; PA and SP noted
    XIFAXAN 200 mgPA and QL apply to 200 mg formulations as listed
    Specialty sourcingSP indicated for some rifaximin formulations
    fosfomycin packet QL
    Fosfomycin packet 3 gQL: 1 packet per 30 days
    Urinary anti-infective groupingFosfomycin listed with QL in urinary anti-infective section
    TierListed as Tier = 2 for packet formulation
    nitrofurantoin macrocrystal QL
    Nitrofurantoin macrocrystal 100 mgQL: 4 capsules per 1 day
    Alternate formulationsOther nitrofurantoin presentations have QL expressed in mL or per day as noted
    TierListed as Tier = 2 in extract for common strengths
    BRAFTOVI QL flag present
    BRAFTOVI 75 mgQL flag present on product line (quantity not specified on line)
    PA/SPPA and SP flags shown for BRAFTOVI in extract
    TierListed as Tier = 6 in extract
    CABOMETYX 20 mg QL (30 tablets per 30 days)
    CABOMETYX 20 mgQL: 30 tablets per 30 days
    PA/SPPA and SP noted for CABOMETYX product lines
    Alternate strengthsHigher strengths listed with same PA/SP controls
    IBRANCE QL (21 per 30 days)
    IBRANCE (palbociclib)QL: 21 capsules/tablets per 30 days; PA and SP noted
    PF notePF (Partial Fill) appears on some oncology entries alongside QL
    TierListed as Tier = 5 (Preferred Specialty)
    LYNPARZA QL (120 per 30 days)
    LYNPARZA oral tabletQL: 120 tablets per 30 days; PA and SP noted
    PF and other flagsPF and SP flags appear on select oncology entries alongside high QL values
    TierListed as Tier = 5 in extract
    PEGASYS syringe QL examples
    PEGASYS syringe examplesPEGASYS subcutaneous syringe 180 mcg/0.5 mL: Notes = PA; SP; QL (2 mL per 30 days)
    PEGASYS solutionPEGASYS subcutaneous solution entry shows PA; SP; QL (4 mL per 30 days) in related listing
    Provider actionPA and SP required where noted for PEGASYS products
    PEMAZYRE QL (14 tablets)
    PEMAZYRE oral tabletQL: 14 tablets per 21 days (PA; SP noted)
    Dose intervalQuantity limit specified per 21-day period for PEMAZYRE
    TierProduct listed with PA and SP controls in extract
    RUBRACA QL (120 Tablets)
    RUBRACA oral tabletQL: 120 tablets per 1 fill (PA; SP; PF may apply)
    PF notePF (Partial Fill) appears on select oncology entries along with QL
    Provider actionPA and SP required where indicated
    GAMMAGARD S-D QL (1 vial) examples
    GAMMAGARD S-D (selected vial sizes)QL: 1 vial per 30 days (PA; SP noted)
    CUVITRUQL: Quantity Limits apply; example QL 0.01 mL per 1 day noted
    GAMMAGARD liquidQL: 1 mL per 28 days for some presentations
    CUVITRU QL examples
    CUVITRUQL: 0.01 mL per 1 day (Quantity Limits apply); PA and SP noted
    IVIG categoryMany immunoglobulin products carry PA, SP, and presentation-dependent QL
    Provider actionSpecialty procurement (SP) required for many IVIG formulations
    GAMMAGARD LIQUID QL
    GAMMAGARD liquid injectionQL: 1 mL per 28 days (PA; SP noted)
    Presentation-dependent QLDifferent vial sizes/presentations have distinct QL entries
    SP requirementMany entries require Pharmacy Advantage sourcing for IVIGs
    GAMMAGARD S-D QL (1 vial per 30 days)
    GAMMAGARD S-DQL: 1 vial per 30 days (PA; SP noted)
    Vial-based limitsQuantity limits often expressed as vials per 30 days for these products
    Claims noteClaims must reflect PA/SP/QL flags to avoid denial
    GAMUNEX-C QL (presentation-dependent)
    GAMUNEX-C presentationsQL varies by presentation: examples include 1 mL per 28 days or 10 mL per 30 days depending on strength
    PA/SPPA and SP indicated on GAMUNEX-C entries
    Provider actionFollow product-specific QL when submitting claims
    HIZENTRA QL
    HIZENTRAQL: 1 mL per 30 days (PA; SP noted)
    Subcutaneous presentationsMultiple syringe and vial sizes listed with QL per mL
    Provider actionSpecialty sourcing and QL apply as annotated
    PRIVIGEN QL
    PRIVIGENQL: 0.01 mL per 1 day (PA; SP noted)
    IVIG groupPRIVIGEN listed among IVIGs with presentation-dependent QL
    Claims reminderClaims should reflect QL units (mL) as specified
    XEMBIFY QL
    XEMBIFYQL: 0.4 mL per 1 day (PA; SP noted)
    Subcutaneous dosingQL expressed in mL per day for subcutaneous presentations
    Provider actionPA and SP apply where indicated
    SHINGRIX QL and age restriction
    SHINGRIXQL: 1 mL per 1 fill; Age restriction: minimum 18 years
    HCR noteSHINGRIX entry includes Health Care Reform (HCR) annotation where applicable
    Provider actionFollow age restriction and QL when administering/claiming
    AUVI-Q QL
    AUVI-QQL: 4 injectors per 1 fill; ALT notes list covered alternatives (other epinephrine auto-injectors)
    Epinephrine auto-injectors (general)QL: 4 units/pens/injectors per fill for various brands (e.g., EPIPEN entries)
    Non-formulary statusSome auto-injector brands listed Non-Formulary with ALT and QL notes
    Epinephrine auto-injectors QL (4)
    Epinephrine auto-injectors (brands)QL: 4 pens per 30 days or 4 units per fill as specified (EPIPEN/AUVI-Q entries)
    ALTCovered alternatives are listed where a product is Non-Formulary
    Provider reminderExceeding QL may trigger denial per formulary controls
    Primatene Mist QL
    Primatene Mist inhalerQL: 11.7 GM per 28 days
    Formulary statusPrimatene Mist listed Non-Formulary with QL noted
    Provider actionQuantity limits apply even to non-formulary inhaler entries
    Spiriva Respimat QL
    Spiriva RespimatQL: 60 GM per 30 days
    Formulation notesSome Spiriva presentations have ALT and per-day QL entries
    Provider actionAdhere to QL when dispensing respimat presentations
    YUPELRI nebulization QL
    YUPELRI nebulization solutionQL: 3 vials per 1 day; SP noted
    Nebulization dosingQL expressed per day for nebulized solutions
    SP requirementYUPELRI entries include SP flag for specialty sourcing
    COSOPT (PF) QL
    COSOPT (PF) ophthalmic 2-0.5%Quantity Limits apply (QL indicated in product line)
    ALTCovered alternatives noted for some ophthalmic drops (e.g., dorzolamide-timolol)
    Provider actionFollow QL and PF flags when submitting claims for PF products
    ADVAIR DISKUS QL
    ADVAIR DISKUSQL: 60 units per 30 days
    PROAIR RESPICLICKQL: 2 inhalers per 30 days (ALT and QL noted)
    Inhaler QL generalMultiple inhaler products list QL as units per 28–30 day period
    PROAIR RESPICLICK QL
    PROAIR RESPICLICKQL: 2 inhalers per 30 days
    ALT notesCovered alternatives listed where product is Non-Formulary
    Provider actionAdhere to QL to avoid denial
    rivastigmine patch QL
    Rivastigmine transdermal patchQL: 30 patches per 30 days
    Formulary placementPatch formulations listed with QL in extract
    Provider actionFollow QL per 30-day supply when dispensing patches
    varenicline pack QL (1 pack per 365 days)
    Varenicline 0.5 mg 42-packQL: 1 pack per 365 days
    Smoking cessation coverageEntries reference HCR and QL limits for cessation products
    Provider actionAnnual QL limit applies to vanenicline pack dispensing
    ELIQUIS DVT-PE 30D START QL (74 tabs)
    ELIQUIS DVT-PE 30D START (74 tabs)QL: 74 tablets per 30 days
    Dose-pack entrySpecific DVT-PE starter pack quantities are specified as QL
    Provider actionSupply limits apply per 30-day starter pack listing
    eltrombopag packet QL
    Eltrombopag oral powder packetsQL: 1 packet per 1 day (PA; SP noted)
    Tablet equivalentsAlternate tablet dosing entries include per-day QL values (varies by strength)
    Provider actionPA and SP apply where indicated for eltrombopag formulations
    ADVATE IV recon soln QL
    ADVATE IV recon solnQL: 1 unit per 1 day
    Multiple specialty injectablesMany clotting-factor and specialty injectables have QL: 1 unit per 1 day (presentation-dependent small-unit values like 0.01 unit/day noted)
    SP/PA flagsPA and SP commonly apply to specialty injectables; follow product-specific requirements
    Multiple specialty injectables QL (1 unit per day examples)
    Multiple specialty injectablesQL: Typically 1 unit per 1 day (or product-specific small units such as 0.01 unit per day where noted)
    ExamplesHemofil M, Jivi, Kogenate, Novoeight, Novoseven RT, and others list QL 1 unit/day or equivalent
    Provider actionPA and SP often required; ensure specialty procurement via Pharmacy Advantage where indicated
    tranexamic acid oral tablet QL
    Tranexamic acid 650 mgQL: 60 tablets per 30 days
    Therapy durationQuantity limit applies per 30-day period as listed
    TierListed as Tier = 2 in extract
    enoxaparin presentations QL examples
    Enoxaparin presentationsQL examples vary by presentation: commonly 18–60 mL per 30 days depending on syringe/kit
    Kit entriesSome enoxaparin kits listed Non-Formulary with SP and QL (1 kit per day) notes
    Provider actionFollow presentation-specific QL when dispensing injectable anticoagulants
    Qfitlia pen QL
    QFITLIA pen/solutionQL: 0.017 mL per day (SP noted)
    Presentation noteSmall mL-per-day QL values are used for some subcutaneous biologic pens
    SP requirementMany such products require specialty sourcing (SP)
    ENTRESTO SPRINKLE QL
    ENTRESTO sprinkle oral pelletQL: 2 tablets per 1 day; NOTES include PA
    Sacubitril-valsartan tabletsQL: 2 tablets per 1 day (TD may apply for some members)
    Provider actionPA noted for ENTRESTO sprinkle formulation; adhere to QL
    icatibant / EVKEEZA / VYNDAQEL QL examples
    Icatibant / EVKEEZA / VYNDAQEL examplesQL: small mL-per-day or capsule counts as noted (e.g., VYNDAQEL QL 4 capsules per day)
    PA/SPPA and SP flags present for these specialty agents
    Provider actionFollow product-specific QL, PA, and specialty sourcing requirements
    Various QL examples (1–4/day, TD, 40 mL/day)
    Various QL examplesExamples across listing include 1–4 units per day for tablets/capsules; 30-day TD supply for new members; 40 mL per day for oral solutions
    TD noteTD = for new to HAP members: one 30-day fill in the first 90 days (applies where noted)
    Per-product applicationApply QL per individual product NOTES field to determine allowed supply

    Where drugs are covered and specialty sourcing

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Legend and abbreviations

    Step therapy program flags and table

    Step Therapy (ST)Description / Application
    ST
    Step Therapy required as indicated on formulary entries; providers must document prior trials of required agents before coverage of the alternative agent. Specific step sequences are defined in product-level edits elsewhere in the formulary.
    Legend CodeMeaning
    ST
    ST = Step Therapy Required (legend). Indicates a required trial of specified drug(s) before coverage of the listed agent.
    ST FlagPresence / Note
    ST flag
    Formulary includes an 'ST' program flag; some drugs in the listing are subject to step therapy where the ST note appears.
    ST as ControlImplication
    Step Therapy (ST)
    ST is noted as a utilization control on the formulary; specific step sequences for individual drugs are maintained in product-level edits and not included in this extract.
    Legend ReferenceText
    ST (legend)
    The formulary legend defines ST = Step Therapy Required; entries annotated with ST must follow the step therapy program as indicated.
    ST Flag MeaningRelated Requirement
    ST flag
    An ST flag indicates the product may require completion of prior step drugs before the requested agent will be covered; details are specified in product-level rules.
    AbbreviationDefinition
    ST
    ST = Step Therapy Required (per formulary legend).
    ProgramExistence
    Step Therapy program
    Formulary includes a Step Therapy (ST) program as part of its utilization management toolkit; ST applies where indicated on product entries.
    ST Flag in FootnoteNote
    ST footnote
    Formulary footnotes and section legends reference ST (Step Therapy Required) as a control that may apply to some products; specific sequences are not shown here.
    ProductNotes
    TRELEGY ELLIPTA
    Listed with NOTES = PA; TD. ST is present in the formulary legend and may apply to other agents in this therapeutic area.
    ScopeApplication
    ST applicability
    Step Therapy applies where specified on formulary entries; providers must meet ST requirements for coverage of listed agents.
    Definition SourceApplicability
    ST defined in legend
    ST is defined in the formulary legend as 'Step Therapy Required' and applies to products annotated with ST in the listing.
    Specialty ProductsST note
    ST for specialty products
    Some specialty products may be subject to ST in addition to PA/SP/QL controls; follow product-level edits and specialty program rules.
    Example productST indicated
    WELCHOL (colesevelam) 625 mg
    Notes in listing: ST (Step Therapy Required); QL (7 tablets per 1 day). This illustrates a product-level ST annotation in the formulary.
    Combination productST presence
    Amlodipine-atorvastatin combinations
    Some combination products (e.g., certain amlodipine-atorvastatin strengths) include TD and ST flags—ST required for some strengths per product notes.

    Policy background and scope

    Specialty drugs are biologics or high‑cost medications that require close monitoring for safety and efficacy and therefore are managed through a contracted specialty pharmacy program. The formulary classifies these products into specialty tiers and applies utilization controls (for example, PA, QL, SP, ST) and specialty sourcing via Pharmacy Advantage to ensure appropriate clinical oversight and distribution.